Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

被引：141

作者：

Luque-Cabal, Maria ^{[1
]}

Garcia-Teijido, Paula ^{[2
]}

Fernandez-Perez, Yolanda ^{[1
]}

Sanchez-Lorenzo, Luisa ^{[1
]}

Palacio-Vazquez, Isabel ^{[1
]}

机构：

[1] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Asturias, Spain

[2] Hosp San Agustin, Dept Med Oncol, Aviles, Asturias, Spain

来源：

CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2016年 / 10卷

关键词：

HER2; overexpression; breast cancer; trastuzumab; resistance; biomarker;

D O I：

10.4137/CMO.S34537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway, cross-talk with estrogen receptors, immune response, cell cycle control mechanisms, and other tyrosine kinase receptors such as insulin-like growth factor I receptor are potential pathways involved in trastuzumab resistance. Different therapeutic interventions targeting these pathways are currently under evaluation.

引用

页码：21 / 30

页数：10

共 113 条

[21] In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib [J].

Chakraborty, Ashok K. ;

Zerillo, Cynthia ;

DiGiovanna, Michael P. .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) :533-544

[22] Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth [J].

Chandarlapaty, S. ;

Scaltriti, M. ;

Angelini, P. ;

Ye, Q. ;

Guzman, M. ;

Hudis, C. A. ;

Norton, L. ;

Solit, D. B. ;

Arribas, J. ;

Baselga, J. ;

Rosen, N. .

ONCOGENE, 2010, 29 (03) :325-334

[23] EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial [J].

Cheng, H. ;

Ballman, K. ;

Vassilakopoulou, M. ;

Dueck, A. C. ;

Reinholz, M. M. ;

Tenner, K. ;

Gralow, J. ;

Hudis, C. ;

Davidson, N. E. ;

Fountzilas, G. ;

McCullough, A. E. ;

Chen, B. ;

Psyrri, A. ;

Rimm, D. L. ;

Perez, E. A. .

BRITISH JOURNAL OF CANCER, 2014, 111 (06) :1065-1071

[24] t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib [J].

Christenson, Jessica L. ;

Denny, Erin C. ;

Kane, Susan E. .

ONCOTARGET, 2015, 6 (32) :33134-33145

[25] Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer [J].

Cortes, Javier ;

Fumoleau, Pierre ;

Bianchi, Giulia Valeria ;

Petrella, Teresa M. ;

Gelmon, Karen ;

Pivot, Xavier ;

Verma, Shailendra ;

Albanell, Joan ;

Conte, Pierfranco ;

Lluch, Ana ;

Salvagni, Stefania ;

Servent, Veronique ;

Gianni, Luca ;

Scaltriti, Maurizio ;

Ross, Graham A. ;

Dixon, Joanna ;

Szado, Tania ;

Baselga, Jose .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1594-1600

[26] Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials [J].

Dahabreh, Issa J. ;

Linardou, Helen ;

Siannis, Fotios ;

Fountzilas, George ;

Murray, Samuel .

ONCOLOGIST, 2008, 13 (06) :620-630

[27] Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancers [J].

Dave, Bhuvanesh ;

Migliaccio, Ilenia ;

Gutierrez, M. Carolina ;

Wu, Meng-Fen ;

Chamness, Gary C. ;

Wong, Helen ;

Narasanna, Archana ;

Chakrabarty, Anindita ;

Hilsenbeck, Susan G. ;

Huang, Jian ;

Rimawi, Mothaffar ;

Schiff, Rachel ;

Arteaga, Carlos ;

Osborne, C. Kent ;

Chang, Jenny C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) :166-173

[28] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response [J].

de Azambuja, Evandro ;

Holmes, Andrew P. ;

Piccart-Gebhart, Martine ;

Holmes, Eileen ;

Di Cosimo, Serena ;

Swaby, Ramona F. ;

Untch, Michael ;

Jackisch, Christian ;

Lang, Istvan ;

Smith, Ian ;

Boyle, Frances ;

Xu, Binghe ;

Barrios, Carlos H. ;

Perez, Edith A. ;

Azim, Hatem A., Jr. ;

Kim, Sung-Bae ;

Kuemmel, Sherko ;

Huang, Chiun-Sheng ;

Vuylsteke, Peter ;

Hsieh, Ruey-Kuen ;

Gorbunova, Vera ;

Eniu, Alexandru ;

Dreosti, Lydia ;

Tavartkiladze, Natalia ;

Gelber, Richard D. ;

Eidtmann, Holger ;

Baselga, Jose .

LANCET ONCOLOGY, 2014, 15 (10) :1137-1146

[29] Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].

Denkert, Carsten ;

Loibl, Sibylle ;

Noske, Aurelia ;

Roller, Marc ;

Mueller, Berit Maria ;

Komor, Martina ;

Budczies, Jan ;

Darb-Esfahani, Silvia ;

Kronenwett, Ralf ;

Hanusch, Claus ;

von Toerne, Christian ;

Weichert, Wilko ;

Engels, Knut ;

Solbach, Christine ;

Schrader, Iris ;

Dietel, Manfred ;

von Minckwitz, Gunter .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113

[30] Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients [J].

DiGiovanna, MP ;

Stern, DF ;

Edgerton, SM ;

Whalen, SG ;

Moore, D ;

Thor, AD .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1152-1160

← 1 2 3 4 5 6 7 8 9 10 →